ASH 2018 | AUGMENT-ing treatment: lenalidomide plus rituximab for R/R indolent NHL

John Leonard

John Leonard, MD, from Weill Cornell Medical College, New York City, NY, discusses the Phase III AUGMENT study (NCT01938001) comparing the use of lenalidomide plus rituximab (R2) vs. rituximab and a placebo in relapsed/refractory indolent non-Hodgkin lymphoma (follicular lymphoma and marginal zone lymphoma). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Leonard reveals that despite additional toxicity, R2 demonstrated superior efficacy over the rituximab arm and provides an important new treatment option in this patient group, with meaningful advantages over single-agent rituximab.

Share this video